ИСТИНА

Background: show the possibilities of immunotherapy as part of the complex treatment of malignant gliomas. Material and Methods: The long-term results of treatment of 200 patients with malignant gliomas of supratentorial localization (anaplastic astrocytomas, glioblastomas, giant cell glioblastomas, gliosarcomas) were evaluated. Of these patients, in addition to standard treatment methods (surgery, radiation therapy and chemotherapy), 100 patients underwent specific antitumor immunotherapy. In 100 patients, only standard methods were used in the complex treatment structure. Follow-up results were considered follow-up data, and a relapse-free period was also evaluated. Results: the implementation of specific antitumor immunotherapy in patients with malignant gliomas was safe and did not lead to an increase in the number of complications compared with the control group. It was revealed that the use of immunotherapy based on autologous dendritic cells, in addition to standard methods of treating patients, increases the average life expectancy (in patients with anaplastic astrocytomas up to 39.3 months (p = 0.001), in patients with glioblastomas up to 20.5 months (p = 0.002)) and the value of the relapse-free period (in patients with anaplastic astrocytomas up to 16.8 months (p = 0.002), in patients with glioblastomas up to 14.4 months (p = 0.003)), provided that three or more courses are carried out. Conducting 1 or 2 courses of immunotherapy does not significantly affect the average life expectancy and median survival of patients. Conclusion: specific antitumor immunotherapy based on autologous dendritic cells improves the long-term results of treatment of patients as part of complex therapy